Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705676 | 1.00 | KDM4E (0.54) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL817396 | 0.83 | MAOB (0.52) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL30586063 | 0.82 | L3MBTL1 (0.57) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL2093115 | 0.80 | KDM4E (0.58) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL9797421 | 0.80 | L3MBTL1 (0.51) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL11515037 | 0.80 | MAOB (0.50) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL7762046 | 0.80 | L3MBTL1 (0.55) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL9811694 | 0.80 | L3MBTL1 (0.51) | KDM4EL3MBTL1POLBALDH1A1MAOB | |
| SCHEMBL23163670 | 0.79 | CHRM2 (0.47) | MAOBMRGPRX4PPARG | |
| SCHEMBL29705642 | 0.79 | CHRM2 (0.47) | MAOBMRGPRX4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| EP-2274266-B1 | PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGUES AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2014-10-15 | — | — | EP | disclosed |
| US-8742143-B2 | Process for the preparation of prostaglandin analogues | SCINOPHARM TAIWAN, LTD. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742143-B2 | Process for the preparation of prostaglandin analogues | SCINOPHARM TAIWAN, LTD. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20130211128-A1 | Process for the Preparation of Prostaglandin Analogues | SCINOPHARM TAIWAN LTD. (TW) | 2013-08-15 | — | — | US | disclosed |
| EP-1527063-B1 | THE 9, 11-CYCLOENDOPEROXIDE PRO-DRUGS OF PROSTAGLANDIN ANALOGUES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALLERGAN INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1527063-A1 | THE 9, 11-CYCLOENDOPEROXIDE PRO-DRUGS OF PROSTAGLANDIN ANALOGUES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | Allergan, Inc. (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6864282-B2 | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma | ALLERGAN, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| WO-2004013119-A1 | THE 9, 11-CYCLOENDOPEROXIDE PRO-DRUGS OF PROSTAGLANDIN ANALOGUES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALLERGAN, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040023954-A1 | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma | ALLERGAN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-4155908-A | PSORIASIS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4128564-A | 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins | MERCK & CO., INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | KDM4E 2114/4885L3MBTL1 2957/4885POLB 2895/4885 |
| US-20040023954-A1 | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma | PTGIS, PTGIR, PTGS1 | KDM4E 3924/4885L3MBTL1 4653/4885POLB 2147/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | KDM4E 1752/4885L3MBTL1 4855/4885POLB 2958/4885 |
| US-20130211128-A1 | Process for the Preparation of Prostaglandin Analogues | PTGIS, PTGES, PTGER1 | KDM4E 3794/4885L3MBTL1 3968/4885POLB 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.